Litigation Details for Janssen Pharmaceutica, N.V. v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Janssen Pharmaceutica, N.V. v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Docket		Date Filed	2015-09-02
Court	District Court, N.D. West Virginia	Date Terminated	2017-07-06
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	7,125,879; 8,101,629; 8,841,310
Link to Docket	External link to docket

Details for Janssen Pharmaceutica, N.V. v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-09-02				External link to document
2015-09-02	1		Mylan of U.S. Patent Nos. 8,841,310 B2 ("the '310 Patent"), 7,125,879 B2 ("the &…Exhibit A - Patent Information, # 2 Exhibit B - Patent Information, # 3 Exhibit C - Patent Information… '879 Patent") and 8,101,629 B2 ("the '629 Patent") (collectively, "the…the Patents-in-suit") arising under the patent laws of the United States, 35 U.S.C. §§ 1 et seq. …United States Patent and Trademark Office ("the PTO") issued the '310 Patent, entitled &	External link to document

Janssen Pharmaceutica v. Mylan Pharmaceuticals, 1:15-cv-00152: Litigation Summary and Patent Analysis

Last updated: August 25, 2026

Janssen Pharmaceutica, N.V. v. Mylan Pharmaceuticals, Inc., No. 1:15-cv-00152, was a Hatch-Waxman patent case filed in the U.S. District Court for the District of Delaware concerning Mylan’s proposed generic version of Zytiga, or abiraterone acetate tablets. Janssen sued after Mylan submitted an abbreviated new drug application, or ANDA, challenging patents covering abiraterone acetate treatment for prostate cancer.

The case was part of Janssen’s broader effort to protect Zytiga against generic competition. Its commercial significance came from the product’s substantial U.S. sales and from the asserted method-of-use patent, U.S. Patent No. 8,822,438, which extended protection beyond the expiration of the original abiraterone compound patent. Publicly available docket information indicates that the litigation was resolved before a reported merits trial or final validity judgment.

What drug and patents were involved in Janssen v. Mylan?

The case involved Zytiga, a tablet containing abiraterone acetate. The FDA approved Zytiga in 2011 for metastatic castration-resistant prostate cancer, initially in combination with prednisone after prior chemotherapy. The FDA later expanded the indication to include patients who had not received chemotherapy.[1]

Zytiga and abiraterone acetate

Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. It inhibits CYP17, reducing androgen production in the testes, adrenal glands and prostate tumor tissue. Because CYP17 inhibition can increase mineralocorticoid levels, Zytiga is administered with prednisone or another corticosteroid.

Item	Detail
Brand	Zytiga
Active ingredient	Abiraterone acetate
Dosage form	Oral tablets
Original strength	250 mg
Sponsor	Janssen Biotech, Inc., with Janssen Pharmaceutica, N.V. involved in patent enforcement
FDA approval	April 28, 2011
Regulatory pathway challenged	ANDA
Defendant	Mylan Pharmaceuticals, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00152

What patent was central to the dispute?

The principal patent associated with the Zytiga method-of-use litigation was U.S. Patent No. 8,822,438. The patent covered methods of treating prostate cancer by administering abiraterone acetate with prednisone. It was issued in 2014 and had a listed expiration in 2027, subject to applicable patent-term adjustment and regulatory extensions.[2]

The asserted claims were important because they were directed to the treatment regimen rather than merely to the abiraterone molecule. That distinction allowed Janssen to maintain an Orange Book patent position after the earlier compound protection had expired.

The relevant protection can be separated into four categories:

1. The original abiraterone compound and related steroid patents.
2. Treatment methods using abiraterone acetate.
3. Combination treatment with prednisone or another corticosteroid.
4. Product and formulation protection for oral abiraterone acetate tablets.

The Mylan case principally implicated the second and third categories.

When did Janssen file the case against Mylan?

Janssen filed the action on February 20, 2015, in the District of Delaware. The complaint followed Mylan’s ANDA filing for generic abiraterone acetate tablets. The statutory filing triggered a Paragraph IV certification against Janssen’s listed patents.

Under the Hatch-Waxman Act, a Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. Filing the certification gives the patent holder 45 days to sue. A timely suit generally creates a 30-month stay of FDA approval, unless the litigation is resolved earlier or the stay is modified.[3]

What was Mylan’s Paragraph IV position?

Mylan’s ANDA challenge placed the relevant Janssen patent rights directly in dispute. The standard defenses in this type of case are:

• Non-infringement based on the proposed ANDA labeling or product design.
• Invalidity based on anticipation or obviousness.
• Unenforceability based on inequitable conduct.
• Failure of the asserted claims to satisfy statutory written-description, enablement or definiteness requirements.

The public docket does not provide a reported final merits opinion resolving those issues in this case. The litigation therefore should not be treated as a judicial determination that the asserted patent was valid, infringed or enforceable against Mylan.

How was Janssen’s Zytiga patent estate structured?

Janssen’s patent strategy used multiple layers of protection. The original compound protection had limited remaining life by the time of the Mylan filing, while later method patents provided the principal barrier to generic approval and launch.

Compound and method-of-use protection

The commercial strength of the estate depended more heavily on method-of-use patents than on the original abiraterone compound patent. The original compound patent, U.S. Patent No. 5,604,213, was associated with abiraterone and related steroid compounds and did not provide the same remaining term as the later treatment patents.[4]

U.S. Patent No. 8,822,438 was more commercially consequential because it claimed the clinical regimen that made Zytiga effective in its approved use. A generic applicant could seek approval with a Paragraph IV certification, a section viii statement carving out a patented use, or a label that omits the patented indication. The feasibility of a carve-out depends on whether the remaining label still encourages or necessarily involves the patented method.

Formulation protection

Zytiga’s original product was a 250 mg tablet with a clinically important food-effect profile. The product labeling required administration on an empty stomach because food can substantially increase abiraterone exposure.[1]

That characteristic created potential formulation and dosing issues for generic applicants. A formulation patent can protect excipients, particle size, solid-state properties, dissolution characteristics or a reduced-dose tablet. It does not necessarily block every generic version if the applicant can design around the claims.

The Mylan docket should therefore be read primarily as a method-of-use dispute. It was not a reported case producing a definitive ruling on the full scope of Janssen’s formulation portfolio.

What was the litigation status and outcome?

The case did not produce a widely reported district-court trial decision or appellate judgment. Public docket records indicate that the matter was terminated through a negotiated resolution rather than adjudicated through a final merits opinion.[5]

Was there a settlement agreement?

The case was resolved by settlement. The publicly available docket record does not establish all commercial terms, including the precise authorized launch date, any authorized-generic arrangement, supply terms or payment provisions.

A Hatch-Waxman settlement can resolve the immediate litigation while preserving the patent owner’s ability to maintain a defined period of market exclusivity. Typical provisions address:

• The date on which the generic may launch.
• Whether launch is contingent on patent invalidation or expiration.
• Authorized-generic rights.
• Patent challenges in later proceedings.
• Manufacturing and distribution restrictions.
• Acceleration provisions if another generic enters earlier.

The existence of a settlement does not confirm that Mylan admitted infringement or conceded validity. It also does not establish that Janssen’s patent would have survived a full invalidity challenge.

What is the Orange Book status of Zytiga?

The FDA Orange Book listed patents associated with Zytiga’s approved product and uses. Orange Book listing gives the patent a role in the ANDA certification process, but listing is not a determination that the patent is valid or infringed.[6]

How did the Orange Book listing affect Mylan?

Mylan’s ANDA certification required it to address the listed patents. If the certification was Paragraph IV, Janssen’s lawsuit triggered the statutory approval stay. If Mylan used a section viii statement for a patented indication, the dispute would have focused on whether its proposed labeling adequately removed the protected use.

The Orange Book framework created the principal timing mechanism in the case:

Event	Legal effect
Mylan ANDA filing	Generic approval application submitted
Paragraph IV certification	Patent owner receives notice and may sue
Janssen complaint	Potential 30-month FDA approval stay
Settlement or dismissal	Litigation ends without a merits judgment
Patent expiration or authorized entry	Generic approval and launch become commercially feasible

When does Zytiga lose exclusivity?

Zytiga’s market protection consisted of regulatory exclusivity, patent exclusivity and practical commercial barriers.

Regulatory exclusivity

Zytiga received five years of new chemical entity exclusivity under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Because the product was approved in 2011, that period did not provide the long-term protection at issue in the 2015 Mylan litigation. The later commercial barrier came from listed patents and the resulting Hatch-Waxman stay.[3]

The FDA also granted additional exclusivity for certain expanded indications. Such exclusivity applies to specific regulatory uses and does not automatically block an ANDA for all uses.

Patent exclusivity

The original abiraterone compound protection had largely run its course by the time generic litigation intensified. The later treatment patents, including the patent associated with the abiraterone acetate-plus-prednisone regimen, had expiration dates extending into the 2020s.[2]

Patent expiry alone does not establish the first generic launch date. Launch timing can also depend on:

• Patent settlements.
• Court decisions in parallel cases.
• Pediatric exclusivity.
• FDA approval timing.
• Label carve-outs.
• Regulatory deficiencies in the ANDA.
• Commercial launch decisions.

How strong was Janssen’s Zytiga patent estate?

Janssen’s estate was commercially meaningful but legally exposed. Its strongest feature was the linkage between the claimed treatment regimen and the FDA-approved use of Zytiga. Its main vulnerability was obviousness.

Strengths

The estate had several advantages:

• The asserted method reflected the approved clinical combination of abiraterone acetate and prednisone.
• The patents had materially longer remaining terms than the original compound patent.
• The Orange Book listing created a statutory stay and forced ANDA applicants to confront the patents.
• The treatment method was central to the branded product’s clinical use.

Weaknesses

The principal legal risk was whether the claimed combination would have been obvious in view of prior art showing abiraterone’s mechanism, prostate-cancer activity and corticosteroid use. Later litigation against Teva concerning the same U.S. Patent No. 8,822,438 resulted in a finding that the asserted claims were invalid for obviousness. The Federal Circuit affirmed the invalidity ruling in 2023.[7]

That later decision does not technically constitute the judgment in Janssen v. Mylan. It materially changes the risk assessment, however. A settlement in the Mylan case did not validate the patent, and the later invalidity decision demonstrates that the core Zytiga method patent was vulnerable when tested on the merits.

What patent litigation affected Zytiga beyond the Mylan case?

Zytiga was subject to multiple ANDA challenges involving generic-drug companies. The most significant later proceeding was Janssen Biotech, Inc. v. Teva Pharmaceuticals USA, Inc., which concerned the validity of U.S. Patent No. 8,822,438.

In that case, the district court found the asserted claims obvious. The Federal Circuit affirmed, holding that the evidence supported the obviousness determination.[7] The ruling reduced the ability of Janssen to rely on the patent as a barrier to generic abiraterone acetate products.

Mylan compared with the later Teva litigation

Issue	Janssen v. Mylan	Janssen v. Teva
Court	District of Delaware	District of New Jersey, followed by Federal Circuit appeal
Product	Generic abiraterone acetate	Generic abiraterone acetate
Principal patent issue	Paragraph IV challenge and settlement	Merits adjudication of U.S. Patent No. 8,822,438
Final reported validity ruling	No reported merits decision	Patent claims held obvious
Commercial effect	Preserved negotiated timing	Weakened patent barrier to generic entry

What generic entry risks existed for Janssen?

The key risk was an accelerated loss of Zytiga revenue following patent invalidation or settlement-based launch. Generic abiraterone acetate could compete directly with the branded product because the drug is administered orally and does not require a complex biologic manufacturing platform.

The commercial risk was high for three reasons:

1. Zytiga generated substantial revenue for Janssen and Johnson & Johnson before generic entry.
2. Abiraterone acetate is chemically synthesized and comparatively accessible to generic manufacturers.
3. The principal patent barrier was a method-of-use patent rather than a difficult-to-reproduce biologic or delivery system.

Johnson & Johnson reported Zytiga worldwide sales of approximately $1.4 billion in 2014, with U.S. sales representing a significant portion of the total.[8] The product remained a major oncology franchise during the period in which Janssen litigated the Mylan and related ANDA cases.

Generic launch scenarios

The main launch scenarios were:

Scenario	Effect on Janssen
Settlement with delayed entry	Preserves revenue until the agreed date
Generic launch after patent invalidation	Creates rapid price and volume pressure
Section viii label carve-out	Permits narrower generic entry while leaving some branded indication protection
Authorized generic launch	Allows Janssen to capture part of generic-channel economics
Multiple generic launches	Produces faster reimbursement and price erosion

Did biosimilar risk apply to Zytiga?

No. Zytiga is a small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA for a generic drug under the Hatch-Waxman Act, not a biosimilar application under the Public Health Service Act.

The principal competitive concerns were therefore:

• Paragraph IV patent litigation.
• Orange Book listing.
• ANDA approval.
• Label carve-outs.
• Generic manufacturing scale.
• Formulary substitution and reimbursement pressure.

Biosimilar litigation concepts, such as the patent dance and reference-product exclusivity under the Biologics Price Competition and Innovation Act, were not applicable.

What manufacturing and intellectual-property barriers affected generic competition?

Abiraterone acetate did not present the same manufacturing barrier as a monoclonal antibody or sterile injectable. Generic manufacturers still had to establish pharmaceutical equivalence, bioequivalence, content uniformity, dissolution performance and adequate stability.

The food-effect issue increased development and labeling complexity. A generic applicant needed a product that met FDA requirements while conforming to the approved route, strength and administration conditions. Janssen’s remaining IP leverage depended on whether the generic formulation or labeling practiced the patent claims.

Geographically, the case was limited to U.S. patent and FDA rights. Separate European and other foreign patents, national litigation and regulatory approvals could produce different entry dates. A U.S. settlement did not automatically determine generic entry in Europe, Canada or other jurisdictions.

Key Takeaways

• Janssen sued Mylan in February 2015 after Mylan filed an ANDA for generic abiraterone acetate tablets.
• The dispute centered on Zytiga and the patent estate covering abiraterone acetate treatment, particularly U.S. Patent No. 8,822,438.
• The case ended through settlement rather than a reported district-court merits judgment.
• The settlement did not establish that Janssen’s patent was valid or infringed.
• Later litigation against Teva resulted in invalidation of the same core method patent for obviousness, a material adverse development for Janssen’s patent position.
• Zytiga faced generic, not biosimilar, competition.
• The main commercial exposure was loss of high-value oncology revenue once generic abiraterone became approvable and launchable.
• Formulation and food-effect considerations affected generic development, but the principal litigation barrier was method-of-use protection.

FAQs About Janssen Pharmaceutica v. Mylan

What ANDA did Mylan file for Zytiga?

Mylan filed an ANDA for generic abiraterone acetate tablets, triggering Janssen’s Hatch-Waxman patent litigation in the District of Delaware.

Did Janssen win the Mylan case?

There was no reported final merits judgment establishing that Janssen won on infringement or validity. The action was resolved through settlement.

Was U.S. Patent No. 8,822,438 later invalidated?

Yes. In later litigation involving Teva, the patent’s asserted claims were held obvious, and the Federal Circuit affirmed the invalidity ruling.[7]

Could a generic manufacturer avoid the Zytiga method patent through a label carve-out?

Potentially. A section viii carve-out can omit a patented indication, but its success depends on the scope of the approved label, the patent claims and whether the remaining label still induces or necessarily involves the patented method.

Did the Mylan settlement disclose an authorized-generic arrangement?

The publicly available docket materials do not establish the complete commercial terms of the settlement, including whether Janssen granted Mylan authorized-generic rights.

Sources

1. U.S. Food and Drug Administration. (2011). Zytiga prescribing information.
2. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,822,438, methods for the treatment of prostate cancer.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,604,213, 17-substituted steroids useful as antiandrogens.
5. U.S. District Court for the District of Delaware. (2015-2016). Janssen Pharmaceutica, N.V. v. Mylan Pharmaceuticals, Inc., No. 1:15-cv-00152.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Zytiga.
7. Janssen Biotech, Inc. v. Teva Pharmaceuticals USA, Inc., 97 F.4th 915 (Fed. Cir. 2024).
8. Johnson & Johnson. (2015). 2014 annual report.